Search research articles
Contact Us
Filters
Showing results (81-90 of 151) with videos related to
Page
of 16
Sort By:
The Lancet. Oncology
|
April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Prostate Cancer and Prostatic Diseases
|
October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
YaoYao Pollock, Matthew R Smith, Fred Saad, et al.
Clinical Genitourinary Cancer
|
March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Investigational New Drugs
|
January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
Robert Jones, Jacqueline Vuky, Tony Elliott, et al.
BJU International
|
June 28, 2024
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy
Axel S Merseburger, Neeraj Agarwal, Anders Bjartell, et al.
The Journal of Urology
|
May 27, 2021
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study
Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Matthew R Smith, Shibu Thomas, Michael Gormley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles, Robert A Huddart, Tony Elliott, et al.
JAMA Network Open
|
October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial
Soumyajit Roy, Shawn Malone, Kevin Wing, et al.
European Urology Oncology
|
December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
Eric J Small, Kim N Chi, Simon Chowdhury, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 151) with videos related to
Sort By:
Page
of 16
The Lancet. Oncology
|
April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Prostate Cancer and Prostatic Diseases
|
October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
YaoYao Pollock, Matthew R Smith, Fred Saad, et al.
Clinical Genitourinary Cancer
|
March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Investigational New Drugs
|
January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
Robert Jones, Jacqueline Vuky, Tony Elliott, et al.
BJU International
|
June 28, 2024
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy
Axel S Merseburger, Neeraj Agarwal, Anders Bjartell, et al.
The Journal of Urology
|
May 27, 2021
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study
Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Matthew R Smith, Shibu Thomas, Michael Gormley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles, Robert A Huddart, Tony Elliott, et al.
JAMA Network Open
|
October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial
Soumyajit Roy, Shawn Malone, Kevin Wing, et al.
European Urology Oncology
|
December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
Eric J Small, Kim N Chi, Simon Chowdhury, et al.
Page
of 16